Testing effectiveness (Phase 2)Ended earlyNCT02906696
What this trial is testing
Bosutinib in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase After Frontline TKI Failure
Who this might be right for
Blasts Under 15 Percent of Bone Marrow Nucleated CellsBlasts Under 15 Percent of Peripheral Blood White CellsBlasts Under 30 Percent of Bone Marrow Nucleated Cells+2 more
M.D. Anderson Cancer Center 8